Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Value of Emicizumab Monitoring With UPLC-MS/MS for Bleeding Risk Prediction in Severe Hemophilia A

NCT04472169 is registered in ClinicalTrials.gov with University Hospital, Lille as lead sponsor.

NCT NCT04472169
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04472169 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Value of Emicizumab Monitoring With UPLC-MS/MS for Bleeding Risk Prediction in Severe Hemophilia A
Lead sponsor
University Hospital, Lille
Phase
Observational
Overall status
Active, not recruiting
Start date
April 13, 2022
Completion date
November 30, 2026
Enrollment
100 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a